Key result
Carvedilol shows no benefit over metoprolol in preserving cardiac function in type 2 diabetes.
Why the study?
Due to additional antioxidant, anti-apoptotic, and alpha1-AR inhibitory properties, carvedilol was hypothesized to improve diabetic cardiac contractility more than metoprolol, but comparative data were needed.
Does carvedilol improve cardiac and myocardial function compared to metoprolol in type 2 diabetes with preserved ejection fraction?
Observational (n=92)
No
Does carvedilol improve cardiac and myocardial function compared to metoprolol in type 2 diabetes with preserved ejection fraction?
Carvedilol and metoprolol demonstrate similar efficacy in preserving myocardial function in the setting of type 2 diabetes with preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
No preference between agents in diabetic models; leaves open whether carvedilol offers advantage in human T2D with preserved EF.
Purpose Increasing cohorts of patients present with diabetic cardiomyopathy, and with no targeted options, treatment often rely on generic pharmaceuticals such as β-blockers. β-blocker efficacy is heterogenous, with second generation β-blocker metoprolol selectively inhibiting β1-AR, while third generation β-blocker carvedilol has α1-AR inhibition, antioxidant, and anti-apoptotic actions alongside nonselective β-AR inhibition. These additional properties have led to the hypothesis that carvedilol may improve cardiac contractility in the diabetic heart to a greater extent than metoprolol. The present study aimed to compare the efficacy of metoprolol and carvedilol on myocardial function in animal models and cardiac tissue from patients with type 2 diabetes and preserved ejection fraction. Methods Echocardiographic examination of cardiac function and assessment of myocardial function in isolated trabeculae was carried out in patients with and without diabetes undergoing coronary artery bypass grafting (CABG) who were prescribed metoprolol or carvedilol. Equivalent measures were undertaken in Zucker Diabetic Fatty (ZDF) rats following 4 weeks treatment with metoprolol or carvedilol. Results Patients receiving carvedilol compared to metoprolol had no difference in cardiac function, and no difference was apparent in myocardial function between β-blockers. Both β-blockers similarly improved myocardial function in diabetic ZDF rats treated for 4 weeks, without significantly affecting in vivo cardiac function. Conclusions Metoprolol and carvedilol were found to have no effect on cardiac function in type 2 diabetes with preserved ejection fraction, and were similarly effective in preventing myocardial dysfunction in ZDF rats.
No takes yet. Share an insight, caveat, or question.
Bussey et al. (2020) conducted an observational in Type 2 diabetes and coronary artery disease with preserved ejection fraction (n=92). Carvedilol vs. Metoprolol (76.0 ± 6.1 mg/day in patients; ~100 mg/kg/day in rats) was evaluated on In vivo cardiac function (echocardiography) and ex vivo myocardial contractile function (developed force, maximal rate of contraction, and relaxation in isolated trabeculae) (p=>0.05). Carvedilol and metoprolol showed no significant difference in preserving ex vivo myocardial contractility or in vivo cardiac function in patients and rats with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: